what is tesamorelin/ipamorelin: Frequently asked questions

Verify reconstitution protocol first—lyophilized peptides degrade rapidly if mixed with non-bacteriostatic water or stored above 8°C post-reconstitution. If storage and handling are correct, the issue is likely endogenous somatostatin dominance or GH receptor resistance. Baseline IGF-1 below 100 ng/mL in adults suggests either pituitary insufficiency (requiring higher GHRH analog doses) or hepatic GH resistance (requiring direct IGF-1 supplementation rather than GH secretagogues). Research teams should measure both GH (via timed blood draws 60–90 min post-injection) and IGF-1 (via fasting morning samples) to isolate the failure point.

Cycle off every 12–16 weeks for 4 weeks to restore baseline receptor sensitivity—continuous administration beyond 16 weeks can reduce GH pulse amplitude by 20–30% due to GHRH receptor downregulation. The ghrelin receptor is less prone to desensitization with ipamorelin's short half-life, but GHRH receptors exhibit tolerance with chronic agonism. Published data on tesamorelin monotherapy showed maintained efficacy across 26 weeks, but studies extending beyond 6 months report diminishing IGF-1increments. A 4-week washout period allows receptor re-expression and restores pulse amplitude to near-baseline levels.

Target visceral adipose tissue (VAT) reduction by measuring waist circumference and DEXA or CT imaging at baseline and 12-week intervals—scale weight is an unreliable marker because GH increases lean mass while reducing fat mass. The COSMOS trial using tesamorelin alone documented 15.2% VAT reduction without significant total body weight change, because concurrent lean mass gain offsets fat loss. Research teams should track fasting insulin and glucose as well—GH can transiently increase insulin resistance during active treatment, though this typically normalizes post-cycle. If fasting glucose rises above 110 mg/dL or HbA1c exceeds 6.0%, consider dose reduction or cycle termination.

Administer both peptides in the same dosing window to maximize synergy—staggering by 6–12 hours separates the GH pulses and loses the additive effect. The mechanism depends on simultaneous GHRH amplification and ghrelin receptor activation converging at the somatotroph cell during the same secretory window. Research protocols that split dosing report 30–40% lower peak GH compared to co-administration, because somatostatin cycles between the two doses independently suppress each pulse.

Resume your regular schedule with the next planned dose. Do not double-dose to 'catch up'. The tesamorelin + ipamorelin blend peptide works by stimulating episodic GH pulses, not by maintaining steady-state serum levels like hormone replacement. Missing two doses means you've had 48 hours without exogenous GH stimulation, but your endogenous pulsatile secretion continues (though at lower amplitude than when augmented by the peptides). When you resume, start with your standard 200–300mcg dose per peptide. Doubling the dose doesn't compensate for missed administrations. It increases the risk of side effects (transient water retention, mild injection site irritation) without proportionally increasing GH output because receptor occupancy saturates at doses above 400mcg per peptide.

Discard the vial. Do not use it. Peptides are temperature-sensitive proteins that denature (lose three-dimensional structure) when exposed to temperatures above 8°C for extended periods. A reconstituted tesamorelin + ipamorelin vial left at room temperature (20–25°C) for 8+ hours has undergone irreversible structural degradation. The solution may still appear clear, but the peptide chains have unfolded and lost receptor-binding capacity. Injecting denatured peptide delivers no GH response. You're administering inactive protein fragments. The 28-day refrigerated stability window assumes continuous storage at 2–8°C; any break in that cold chain restarts the degradation clock at an accelerated rate.

Verify three factors: dosing accuracy, administration timing, and peptide integrity. First, confirm you're injecting the correct volume. 0.2–0.3mL of properly reconstituted solution at 1mg/mL concentration delivers 200–300mcg per peptide. Under-dosing (e.g., injecting 0.1mL thinking it's sufficient) produces subtherapeutic GH elevation. Second, injection timing relative to meals matters: administering the blend within two hours of eating blunts GH response because elevated glucose and insulin suppress somatotroph activity. Third, if the peptide was stored incorrectly at any point (shipped without cold packs, left in a warm car, stored in a non-calibrated refrigerator running above 8°C), potency loss is the likely explanation. GH response variability also exists between individuals. Some subjects are naturally high responders while others require dose adjustments.

Complete the current draw, but minimize air injection on all future draws to reduce contamination risk. The pressure differential created by injecting air forces the plunger to compress slightly, which can pull airborne bacteria or particulates backward through the needle when you withdraw it from the vial. This is a cumulative sterility risk. One air injection won't immediately contaminate the vial, but repeated air injections over 10–14 doses increase the likelihood of introducing microorganisms that bacteriostatic water alone cannot suppress. The correct technique: insert the needle, invert the vial, and allow the vacuum to draw solution into the syringe naturally.

Refrigerate it immediately and discard the vial if it's been at room temperature longer than 48 hours. Tesamorelin undergoes conformational degradation above 8°C. The hexenoyl group oxidizes, and the peptide loses receptor binding affinity. A single 24-hour ambient temperature exposure may reduce potency by 15–25%, but the peptide won't appear visually different (no color change, no cloudiness). The ipamorelin component will remain stable, but the blend as a whole is compromised. Temperature-sensitive peptides like tesamorelin don't 'partially work' after heat exposure. They either bind to receptors with full affinity or they don't.

Contact the supplier immediately and request a replacement if the cold pack was completely melted on arrival. Lyophilized peptides are more stable than reconstituted solutions, but tesamorelin is still heat-sensitive in powder form. If the package was shipped with inadequate cold chain protection and the powder arrived at ambient temperature, oxidative degradation may have already begun. Reputable peptide suppliers use insulated shippers with gel packs calibrated to maintain −20°C for 48–72 hours in transit. If yours didn't, that's a red flag about their handling protocols. Our team sources peptides exclusively from facilities that provide temperature-logging documentation with every shipment.

Discard the vial immediately and do not inject. Cloudiness or particulate matter indicates protein aggregation, microbial contamination, or incomplete dissolution. Any of which compromises bioactivity and sterility. Properly reconstituted tesamorelin + ipamorelin blend should appear as a clear, colorless solution with no visible sediment. If cloudiness appears after refrigeration, do not attempt to re-dissolve by warming or shaking; the peptide structure has already been compromised. Always inspect vials under bright light before each injection, and never inject a solution that has changed appearance since initial reconstitution.

Verify reconstitution technique, storage conditions, and injection timing first. The most common cause of subtherapeutic response is peptide degradation from improper storage. Tesamorelin degrades rapidly at temperatures above 8°C, and ipamorelin loses bioactivity when exposed to light for prolonged periods. If storage and handling are confirmed correct, assess subject-specific factors: pre-existing pituitary dysfunction, high baseline somatostatin tone, or circulating anti-GH antibodies can all blunt secretagogue response. Some research models require dose titration upward to 3–4mg tesamorelin + 300–500mcg ipamorelin to overcome endogenous inhibitory tone. Serial IGF-1 measurement is more reliable than single-timepoint GH sampling, as GH has a short half-life (10–20 minutes) and fluctuates dramatically; IGF-1 reflects cumulative GH exposure over 12–24 hours and is less susceptible to timing artifacts.

Rotate injection sites to prevent localized lipohypertrophy and reduce mechanical irritation from repeated subcutaneous trauma. Mild erythema (redness) or pruritus (itching) at the injection site typically resolves within 4–8 hours and is attributed to histamine release from subcutaneous mast cells responding to the peptide bolus and benzyl alcohol preservative. If reactions persist beyond 12 hours, consider switching to preservative-free sterile water for reconstitution (though this reduces shelf life to 7–10 days). Persistent swelling, induration, or pain lasting beyond 24 hours may indicate infection or allergic hypersensitivity. Discontinue use and consult the supervising investigator or institutional biosafety officer immediately.